MTOR and COVID-19: Some recommendations for the management of immunosuppressant medications included reducing or discontinuing certain immunosuppressants, such as mycophenolate or mTOR inhibitors while maintaining calcineurin inhibitors and corticosteroids at minimal effective doses.Others recommended a more specific approach for the management of immunosuppressants in the setting of COVID-19 in kidney transplant patients that involved a 50% reduction in antimetabolite dose or complete withdrawal on a case-by-case basis.